Learn how how pharma and biotech sponsors and sites can leverage best practices throughout site activation – particularly in regard to feasibility, contracts, and site documents – in a new educational webinar.
LONDON UK and PHILADELPHIA PA (PRWEB UK) 28 September 2017
DrugDev, a QuintilesIMS company, will reveal how sponsors and sites can leverage best practices throughout the site activation process – particularly in regard to feasibility, contracts, and site documents – in a new educational webinar. The webinar also will discuss how sites can be affected by Good Clinical Practice (GCP) during selection and activation, and address how to avoid common site mistakes.
Webinar: Cross-Functional Strategies for Successful Site Startup Planning
Date: 3 October 2017
Time: 2-3pm BST (9-10am ET)
- Jim DiCesare, DrugDev Vice President, SiteStart
- Virginie Schau, DrugDev Project Lead, SiteStart
Registration: Register Here
Clinical trials that miss deadlines for site selection, feasibility, enrolment, or activation incur skyrocketing costs. For example, Cutting Edge Info says trial delays can cost up to $8 million in lost revenue for each day a drug is delayed. In this webinar Jim DiCesare, DrugDev Vice President, SiteStart and DrugDev Project Lead, SiteStart Virginie Schau will discuss strategies and tactics to ensure sponsors have the most efficient and successful study startup possible. Attendees will learn:
- How to create a tailored and proactive approach to study startup
- Why proactive planning supported by technology to monitor startup and study surveillance is an essential component to study startup
About the Presenters
Jim DiCesare is passionate about delivering innovative site activation services and a beautiful technology experience for DrugDev customers. Jim’s deep site activation knowledge gained over 18 years of leading clinical operations teams has enabled DrugDev to offer a best-in-class site activation service to their sponsor and CRO clients. Jim is a frequent speaker at industry conferences and has written for a variety of publications. He has a B.S. in Accounting from Kutztown University.
Virginie Schau has a deep background in site identification, site management, and contract management services. Her experience includes managing Ethics Committee submissions throughout Europe, the Middle East, and Africa for interventional and observational studies, ESD collection and review, and contract and budget negotiations. Prior to DrugDev Virginie had roles of progressively increasing responsibility at Eli Lilly, PRA Health Sciences, and at Covance where she specialized in contract template development, negotiations, CDA, deliverables, and legal review.
DrugDev, a QuintilesIMS company, helps the world do more trials through industry-wide collaboration, standardization and a beautiful technology experience. DrugDev Spark™, the unified clinical operations suite, is comprised of proven solutions used by 85 sponsors and CROs on over 2,000 clinical trials to transform the quality and efficiency of clinical trials from startup through closeout. DrugDev Spark is powered by the DrugDev Golden Number, the award-winning universal identifier for global site facilities and investigators used by TransCelerate and the Investigator Databank. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust DrugDev by scheduling a demo of DrugDev Spark at drugdev.com.